The University of Texas MD Anderson Cancer Center and Sibylla Biotech announced a strategic collaboration agreement to discover and develop novel small-molecule cancer therapies known as folding interfering degraders, which disrupt the proper folding of target proteins and lead to their degradation.
Atlantic Health System, an integrated health care system setting standards for quality health care, and Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, have announced Atlantic Health System’s plans to acquire and install a MEVION S250-FIT Proton Therapy System at the Carol G. Simon Cancer Center.Â
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center and the IU School of Medicine have discovered that Black patients with breast cancer who are treated with docetaxel experience less peripheral neuropathy. Their findings represent an important shift in knowledge about a patient population who’ve historically been underrepresented in breast cancer research.
Data from the IMROZ phase III trial demonstrated Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone followed by Sarclisa-Rd (the IMROZ regimen) significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with newly diagnosed multiple myeloma not eligible for transplant.Â
Detailed positive results from the DESTINY-Breast06 phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy in patients with HR-positive, HER2-low metastatic breast cancer and the overall trial population (patients with HR-positive, HER2-low and HER2-ultralow [defined as IHC 0 with membrane staining] expression) following one or more lines of endocrine therapy.Â
Bristol Myers Squibb presented results from the phase III CheckMate-9DW trial evaluating the dual immunotherapy combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to investigator’s choice of lenvatinib or sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma. Results from the study were featured in a late-breaking oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting.Â
Bristol Myers Squibb announced results from three updated analyses from the CheckMate-77T, CheckMate-816, and CheckMate-9LA studies supporting Opdivo (nivolumab) and Opdivo-based combinations in early stage and advanced non-small cell lung cancer. Data were presented at the 2024 American Society of Clinical Oncology Annual Meeting.
According to preliminary data from a multi-institution phase III trial led by researchers at MD Anderson Cancer Center, intensity modulated proton therapy achieved similar clinical outcomes and offered significant patient benefits when compared to traditional intensity modulated radiation therapy as part of chemoradiation treatment for patients with oropharyngeal cancer.Â
The novel anti-CD19 autologous CAR T-cell therapy obecabtagene autoleucel achieved durable remissions in 40% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia without a subsequent stem cell transplant, according to results from the phase Ib/II FELIX clinical trial presented by Elias Jabbour, professor of leukemia at MD Anderson, at the 2024 American Society of Clinical Oncology Annual Meeting.Â
When combined with azacitidine, a 7-day course of venetoclax demonstrated similar remission rates and was more tolerable compared to the standard 28-day course for older or chemotherapy-ineligible patients with newly diagnosed acute myeloid leukemia. Results from the retrospective multi-center analysis were presented by Alexandre Bazinet, assistant professor of leukemia at MD Anderson, at the 2024 American Society of Clinical Oncology Annual Meeting.
